Host:Rabbit
Target Protein:HLA-DQA1
IR:Immunogen Range:
Clonality:Monoclonal
Isotype:IgG
Entrez Gene:3117
Swiss Prot:P01909
Source:KLH conjugated synthetic peptide derived from human HLA-DQA1:
Purification:affinity purified by Protein A
Storage:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Background:Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accomodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Size:50ul
Concentration:1mg/ml
Applications:WB(1:500-2000)
IP(1:10-50)
IHC-P(1:50-200)
IHC-F(1:50-200)
IF(1:50-200)
Cross Reactive Species:Human
Mouse
Rat
.
本產(chǎn)品僅供科研使用。不能用于人和動物治療等其它臨床診斷使用!
關(guān)鍵字: CD;CELIAC1;DC alpha;DC1;included;
上海滬震實業(yè)有限公司是一家集研發(fā)、生產(chǎn)和銷售于一體的生命科學(xué)實驗室產(chǎn)品生物科技企業(yè)。主營產(chǎn)品:試劑盒,ELISA試劑盒,抗體,重組蛋白,血清,胎牛血清,細(xì)胞,原代細(xì)胞 細(xì)胞培養(yǎng)試劑,常用生化試劑。